Abeona Therapeutics Inc (ABEO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) has a cash flow conversion efficiency ratio of -0.137x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.50 Million) by net assets ($128.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Abeona Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Abeona Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Abeona Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abeona Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abeona Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Abeona Therapeutics Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orizon Valorização de Resíduos S.A
SA:ORVR3
|
0.002x |
|
Eyepoint Pharmaceuticals Inc
NASDAQ:EYPT
|
-0.297x |
|
Channel Well Technology Co Ltd
TWO:3078
|
0.054x |
|
Rishabh Instruments Limited
NSE:RISHABH
|
0.045x |
|
Taiwan Taxi Co Ltd
TWO:2640
|
0.066x |
|
CapsoVision, Inc. Common Stock
NASDAQ:CV
|
-0.638x |
|
JinGuan Electric Co Ltd
SHG:688517
|
0.020x |
|
Putnam Premier Income Trust
NYSE:PPT
|
N/A |
Annual Cash Flow Conversion Efficiency for Abeona Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Abeona Therapeutics Inc from 1995 to 2025. View Abeona Therapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.22 Million | $-76.33 Million | -0.479x | +62.32% |
| 2024-12-31 | $44.03 Million | $-56.02 Million | -1.272x | +49.04% |
| 2023-12-31 | $14.83 Million | $-37.01 Million | -2.496x | -53.63% |
| 2022-12-31 | $26.76 Million | $-43.48 Million | -1.625x | -4.84% |
| 2021-12-31 | $42.37 Million | $-65.67 Million | -1.550x | -353.87% |
| 2020-12-31 | $102.55 Million | $-35.02 Million | -0.341x | +3.01% |
| 2019-12-31 | $178.43 Million | $-62.82 Million | -0.352x | -20.67% |
| 2018-12-31 | $134.04 Million | $-39.11 Million | -0.292x | -116.40% |
| 2017-12-31 | $170.10 Million | $-22.93 Million | -0.135x | -2.67% |
| 2016-12-31 | $99.10 Million | $-13.01 Million | -0.131x | +14.67% |
| 2015-12-31 | $67.72 Million | $-10.42 Million | -0.154x | +53.99% |
| 2014-12-31 | $4.82 Million | $-1.61 Million | -0.335x | -494272.28% |
| 2013-12-31 | $-14.78 Million | $1.00K | 0.000x | -100.03% |
| 2012-12-31 | $-17.08 Million | $-3.96 Million | 0.232x | -46.41% |
| 2011-12-31 | $-17.61 Million | $-7.61 Million | 0.432x | +31.01% |
| 2010-12-31 | $-20.80 Million | $-6.86 Million | 0.330x | +296.06% |
| 2009-12-31 | $-26.99 Million | $-2.25 Million | 0.083x | -85.80% |
| 2008-12-31 | $-11.19 Million | $-6.56 Million | 0.586x | -91.75% |
| 2007-12-31 | $681.00K | $4.84 Million | 7.112x | +3491.03% |
| 2006-12-31 | $-9.89 Million | $-1.96 Million | 0.198x | -88.51% |
| 2005-12-31 | $-4.24 Million | $-7.30 Million | 1.723x | +26.45% |
| 2004-12-31 | $-6.66 Million | $-9.08 Million | 1.363x | +24.75% |
| 2003-12-31 | $-5.83 Million | $-6.36 Million | 1.092x | +106.21% |
| 2002-12-31 | $489.00K | $-8.60 Million | -17.577x | -2926.58% |
| 2001-12-31 | $9.08 Million | $-5.27 Million | -0.581x | -101.19% |
| 2000-12-31 | $15.00 Million | $-4.33 Million | -0.289x | +67.98% |
| 1999-12-31 | $3.60 Million | $-3.25 Million | -0.901x | +49.30% |
| 1998-12-31 | $1.80 Million | $-3.20 Million | -1.778x | +70.65% |
| 1997-12-31 | $599.00K | $-3.63 Million | -6.057x | -821.68% |
| 1996-12-31 | $4.06 Million | $-2.67 Million | -0.657x | -268.38% |
| 1995-12-31 | $1.69 Million | $658.00K | 0.390x | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more